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The 99mTc-MIBI radiopharmaceutical has been used in nuclear medicine in 
Indonesia for myocardial imaging. BATAN researchers have mastered the 
technology to manufacture MIBI as a liophylized kit. A reformulation of MIBI 
radiopharmaceutical has been conducted to improve the stability of the kit 
especially in the liquid-phase kit. Basically, radiopharmaceuticals in liquid form are 
not different from the dry kit. However in the manufacturing of liquid-phase kit, 
lyophilization process was not done. To improve the stability of liquid kit, a 
reformulation of the components was conducted by using two separate vials 
(Formulation 2) and the characteristics were compared with the one-vial 
formulation (Formulation 1). The MIBI Formulation 2 consists of two vials, vial A 
containing 0.06 mg of SnCl2 2H2O and 2.6 mg Sodium Citrate 2H2O and vial B 
containing 0.5 mg of [Cu(MIBI)4]BF4, 1 mg of cysteine hydrochloride, and 20 mg 
of mannitol. The purposes of this study were to determine the stability of two 
different formulations of MIBI as a liquid-phase kit, to compare their stability in 
different storage condition such as in refrigerator and freezer, and to compare the 
ratio of activities attained between target and nontarget organs after injection to 
animal model. As a diagnostic agent, MIBI was reconstituted with Technetium-99m 
as radionuclide tracer to 99mTc-MIBI labeled compound. The radiochemical purity 
of 99mTc-MIBI was determined by chromatography method using alumina thin-layer 
chromatography paper as the stationary phase and ethanol 95% as the mobile phase. 
The results showed MIBI Formulation 2 has a higher stability than Formulation 1. 
Formulation 2 also maintained a 96.68% radiochemical purity under 52-day storage 
and attained a target-to-nontarget activity ratio of 8.22. 
 
© 2016 Atom Indonesia. All rights reserved 
 
 
INTRODUCTION 
 
Radiopharmaceuticals are radioactive 
compounds used for the diagnosis and therapeutic 
treatment of human diseases [1,2]. In diagnostic 
applications, radiopharmaceuticals in the form of 
compounds that has been labeled with radioactive 
material are used as tracers; they are used to detect 
the interference and obstruction in organs and the 
existence of infections and tumors in the organs. 
Methoxyisobutylisonitrile (MIBI) is a ligand that 
was introduced in early 90s and is used in the 
manufacture of radiopharmaceuticals for myocardial 
perfusion diagnosis and also for cancer detection   
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[3-5]. MIBI ligands are successfully synthesized at 
BATAN Bandung and have been utilized in the 
nuclear medicine at various hospitals in Indonesia 
such as the Hasan Sadikin Hospital in Bandung [6]. 
The 
99m
Tc-MIBI radiopharmaceutical is a 
complex compound, a lipophilic agent with a 
positive charge which is easily taken up by 
myocardial cells through passive diffusion and 
localized in the mitochondria [1,7]. The 
99m
Tc-MIBI 
complex is stabilized by six isonitrile ligand groups 
in the +1 oxidation state, forming a stable octahedral 
complex and it is stable in air and water [3,8,9]. 
Therefore, the MIBI radiopharmaceutical is 
widely used for the diagnosis of myocardial 
perfusion in order to evaluate ischemic                          
heart diseases and locate abnormal myocardium               
[9]. Several studies also developed this 
Atom Indonesia Vol. 42  No. 1  (2016) 27 - 32 
 
 
Atom Indonesia 
 
Journal homepage: http://aij.batan.go.id 
 
 
 
 
27 
I. Daruwati  et al. / Atom Indonesia Vol. 42  No. 1  (2016)  27 - 32 
radiopharmaceutical to diagnose parathyroid gland 
disorders in cases of hyperthyroidism and breast 
cancer (oncology) [10-12]. In addition, the MIBI 
radiopharmaceutical can also be used for renal 
oncocytomas, diagnosis of metastatic cancer, 
detection of recurrent gliomas after radiotherapy, 
and evaluation of response to chemotherapy [11,13]. 
The MIBI radiopharmaceutical was 
formulated in dry form by lyophilization process 
using a freeze dryer; the result has a longer shelf life 
than does the liquid form. The previous research 
was conducted in a single vial liquid from formula 
[6]. The aim of this reseach is to evaluate the 
stability of the two different formulations and to 
compare them. The first formula is a single vial 
containing both the ligand (MIBI) and the reducing 
agent (SnCl2). The second formula separates the 
ligand and the reducing agent in different vials to 
improve stability during storage. 
 
 
EXPERIMENTAL METHODS 
 
Labeling MIBI liquid phase kit formulation 1 
and formulation 2 with technetium-99m  
For further work, two different MIBI 
radiopharmaceutical formulations were prepared. 
Henceforth, they will be referred to as Formulation 
1 and Formulation 2. 
The Formulation 1 of MIBI was dissolved with                   
0.5 mL of aquabidest and then stirred with a vortex 
mixer until homogeneous. Approximately 1.0 to                 
5.0 mL of 5-10 mCi
 99m
Tc-pertechnetate (from                
PT INUKI) was added to the MIBI liquid kit, then 
restirred with a vortex mixer for a few seconds and 
heated in a boiling water bath for 10 minutes.                
The Formulation 2 of MIBI consisted of 2 vials               
(A and B). A precisely-measured 0.5 mL of A vial 
was inserted into B vial, then added with 1.0 to               
5.0 mL of 
99m
 Tc-pertechnetate (5-10 mCi) to the 
MIBI liquid kit, then stirred with a vortex for a few 
seconds and heated in a boiling water bath for               
10 minutes [6]. The composition of formulation 1 
and 2 are shown in Table 1.  
 
Table 1.  Formulation of MIBI liquid phase kit 
 
Formulation 1 Formulation 2 
 
[Cu(MIBI)4]BF4        0.5   mg 
SnCl2 2H2O            0.06  mg 
Na-citrate. 2H20     2.6    mg 
Cisteine HCl          1.0    mg  
Mannitol                20     mg 
 
Vial A  
SnCl2 2H2O           0.06 mg 
Na-citrate. 2H20     2.6  mg 
Vial B  
[Cu(MIBI)4]BF4       0.5 mg 
Cisteine HCl          1.0  mg  
Mannitol                20   mg  
Radiochemical purity determination of MIBI 
liquid phase [6,14] 
The radiochemical purity of 
99m
Tc-MIBI was 
determined by paper chromatography. A precisely-
measured 5 µL of 
99m
Tc-MIBI was spotted on 
alumina thin layer chromatography paper          
(TLC-Al2O3) as the stationary phase, then eluted 
with absolute ethanol as the mobile phase. Alumina 
TLC paper sheets were dried at 80ºC, then cut after 
each 1 cm and counted using a single-channel 
gamma counter. The purity of 
99m
Tc-MIBI was 
calculated based on the separation of impurities                
with different retention factors (RF), namely                 
RF = 0.6-0.7 (
99m
TcO4); RF = 0.0 (
99m
Tc02) and               
RF = 0.8-1.0 (
99m
Tc-MIBI) [6]. 
 
 
Stability of the MIBI liquid phase kits under 
storage  
MIBI Liquid Kit formulations 1 and 2 were 
stored in freezer and their stability was periodically 
tested. Their stability was determined by labeling 
techniques with technetium-99m, and then the 
radiochemical purity of 
99m
Tc-MIBI was calculated. 
The percentage of 
99m
Tc-MIBI radiochemical              
purity must fulfill the requirements of a good 
radiopharmaceutical (>90%) [15]. 
 
 
Stability of MIBI liquid phase kit at room 
temperature  
The stability of MIBI liquid phase kit                   
was tested by labeling and radiochemical                     
purity determination. The 
99m
Tc-MIBI 
radiopharmaceuticals were stored at room 
temperature for 4 hours and were tested every      
one hour. 
 
 
Determination of  ratio target and non-target 
in animal model 
A precisely-measured 200 μCi / 200 μL 
99m
Tc-MIBI radiopharmaceutical with high 
radiochemical purity (>90%) was intravenously 
injected through the tail of Wistar rats.                  
The animal models were killed at 30 minutes       
after injection, and then the organs such as        
heart, liver, kidneys and lungs were collected       
and counted using a single-channel analyzer.       
The ratio between activities attained in              
target organs and in non-target organs was 
calculated.  
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RESULTS AND DISCUSSION 
 
MIBI liquid kits were produced in two 
different formulas, namely Formulation 1 in the 
single vial and Formulation 2 in two vials (vials A 
and B), as shown in Fig. 1. The separation of tin 
chloride in the different vial is to prevent the 
reaction of tin chloride with other compounds, 
especially in liquid form. 
 
 
 
Fig. 1. MIBI Liquid Phase Kit  (Formulation 2). 
 
Basically, the manufacturing process of liquid 
phase kit is similar to dry kit. All the activities 
carried out in aseptic conditions in a sterile room, 
without the lyophilization process. The final 
products of liquid kit were stored in a lower 
temperature such as refrigerator (4C) and                   
freezer (<0ºC). 
As shown in Fig. 2, the stability of liquid kit 
MIBI Formulation 1 was tested by storage in a 
refrigerator (4C). The results showed that 
radiochemical purity of 
99m
Tc-MIBI was decreased 
to 65% on day 23.  
 
 
Fig. 2. Stability of liquid kit MIBI Formulation 1 in the 
refrigerator (4C)  
 
As shown in Fig. 3, liquid kit MIBI 
Formulation 2 showed higher stability than 
Formulation 1 until day 52 under the storage in the 
freezer; Formulation 2 maintains a radiochemical 
purity of 96.68%. Formulation 1’s radiochemical 
purity decreased to 50.54% after 17 days of storage. 
Thus, it can be concluded that Formulation 2, which 
separates its tin chloride in a different vial, can 
prevent the reaction between the tin chloride and 
other components, because tin chloride as a 
reducing agents is very sensitive to oxidation [15].  
 
 c  
-
  Citrate 
    
→    c-Citrate   (1) 
 
[Cu( )(    ) ]
    c-Citrate 
heat
→  [ c( )(    )6]
   (2) 
 
The reaction of MIBI complex based on ligand 
exchange is stated in equations (1) and (2). Cysteine 
and stannous chloride are reducing agents. Manitol 
is a bulking agent and forms a weak complex with 
reduced technetium. Under heating process, copper-
MIBI complex is broken and it releases a MIBI 
ligand with an isonitrile group. The MIBI ligands 
displace citrate from the preformed 
99m
Tc-citrate 
intermediate to form 
99m
Tc-sestamibi. After the 
99m
Tc-MIBI complex was formed, the 
99m
Tc-citrate 
no longer remains and its radiochemical impurity 
cannot be determined. 
 
 
 
 
Fig. 3. Stability of liquid kit MIBI Formulation 1  and 
Formulation 2 which storage in the  Freezer (<0ºC). 
 
 
Figure 4 shows the effect of the final volume                   
of 
99m
Tc-MIBI on its radiochemical purity.                        
The maximum volume actually used for labeling 
liquid kit was 5 mL with a radiochemical purity               
of more than 90%. Radiation causes decomposition 
of water, a main ingredient of most 
radiopharmaceuticals, leading to the production of 
reactive hydrogen atoms and hydroxyl radicals, 
hydrated electrons, hydrogen, hydrogen ions, and 
hydrogen peroxide. The last substance mentioned is 
formed in the presence of oxygen radicals, 
originating from the radiolytic decomposition of 
dissolved oxygen. Many radiopharmaceuticals show 
improved stability if oxygen is not present [14]. 
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Fig. 4. Effect of final volume to radiochemical purity of  99mTc-
MIBI Formulation 2. 
 
 
After reconstitution, 
99m
Tc-MIBI from 
Formulation 2 showed good stability at room 
temperature until 4 hours with a radiochemical 
purity staying more than 90% (95.73%) (Fig. 5).                
It coresponds with previous research by Nurlaila, 
which found that 4 hours after reconstitution, the 
radiochemical purity was still high (>95%) [6]. 
High radiochemical purity will give an overview to 
practitioners in hospitals that 
99m
Tc-MIBI could be 
given to the patient until 4 hour of reconstitution.  
 
 
 
Fig. 5. Stability of 99mTc-MIBI Formulation 2 in the room 
temperature (25 C). 
 
 
Myocardial imaging is performed by 
intravenous injection at rest and under stress 
condition. In this study, scanning of 
99m
Tc-MIBI is 
performed at rest condition as early as 30 min              
after injection using Wistar Rat (Fig. 6). After 
intravenous administration, 
99m
 Tc-MIBI is rapidly 
cleared from the blood, with only 8% of the 
administered activity remains in the circulation 5 
min after injection [1].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Scanning of 99mTc-MIBI 30 minutes after iv injection of 99mTc-MIBI using Wistar rat. 
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The scanning showed high accumulation of 
99m
Tc-MIBI at heart, liver, and kidney. Then, 
accumulation of 
99m
Tc-MIBI occurs by 
biodistribution. An ideal radiopharmaceutical for 
imaging should attain a target-to-nontarget activity 
ratio of greater than 3.0. The tracer is excreted 
through both the hepatobiliary system (33% at              
48 hours) and the urine (27% at 24 hours), and its 
biological half-life in the myocardium is 
approximately 7 hours [1]. 
Figure 7 shows heart-to-liver activity ratio of 
5.46 and 8.22 for Formulation 1 and Formulation 2, 
respectively. This suggests that Formulation 2 gives 
a higher ratio than Formulation 1. Figure 8 shows 
that Formulation 2 attains lung- and kidney-to-heart 
ratios of 4.32 and 0.99 respectively. This result 
showed higher ratios than other -research using 
nitrido complex 
99m
TcN-MIBI [16].  
 
 
 
 
Fig. 7.  Heart to hepar  ratio,  30 minutes after iv injection of 
99mTc-MIBI using Wistar rat. 
 
 
Fig. 8. Target to non target  ratio,  30 minutes after iv injection 
of 99mTc-MIBI Formulation 2  to animal model. 
CONCLUSION 
The two-vial formulation (Formulation 2) of 
MIBI liquid kit exhibits a higher stability than the 
one-vial Formulation 1. The Formulation 2 liquid 
kit remains stable until 52 days of storage inside a 
freezer and for 4 hours after reconstitution, and with 
a maximum final volume of 5 mL its radiochemical 
purity stay greater than 90%. This result showed 
higher target-to-nontarget ratios than using nitrido 
complex 
99m
TcN-MIBI. In the next step to final 
product, this research will countinue with the 
development of dry and sterile MIBI kit with 
lyophilization process. 
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